Imaging, diagnosis and treatment of angiogenesis-related diseases comprising ecsm4
CA 2427310 C · Owner: Cancer Research Technology Limited · Inventors: Bicknell, Roy; Huminiecki, Lukasz
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present disclosure relates to endothelial cell-specific molecule 4 genes and encoded , polypeptides and materials and uses thereof in the imaging diagnosis and , treatment of , conditions involving the vascular endothelium including cancer, psoriasis, diabetic retinopathy atherosclerosis or menorrhagia.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 6, 2001 and granted December 17, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 6, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 6, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.